Synthesis and structure-activity relationship (SAR) study Of L-amino acid-based N-type calcium channel blockers are described. The compounds synthesized were evaluated for inhibitory activity against both N-type and L-type calcium channels focusing on selectivity to reduce cardiovascular side effects due to blocking of L-type calcium channels. In the course of screening of our compound library, N-(t-butoxycarbonyl)-L-aspartic acid derivative la was identified as an initial lead compound for a new series of N-type calcium channel blockers, which inhibited calcium influx into IMR-32 human neuroblastoma cells with an IC50 Of 3.4muM. Compound la also exhibited blockade of N-type calcium channel current in electrophysiological experiment using IMR-32 cells (34% inhibition at 10 muM, n = 3). As a consequence of conversion of amino acid residue of I a, compound 12a, that include N-(t-butoxycarbonyl)-L-cysteine, was found to be a potent N-type calcium channel blocker with an IC50 of 0.61 muM. Thus, L-cysteine was selected as a potential structural motif for further modification. Optimization of C- and N-terminals Of L-cysteine using S-cyclohexylmethyl-L-cysteine as a central scaffold led to potent and selective N-type calcium channel blocker 21f, which showed improved inhibitory potency (IC50 0.12 muM) and 12-fold selectivity for N-type calcium channels over L-type channels. (C) 2003 Elsevier Science Ltd. All rights reserved.